Candida albicans – mycolab.ai

Baicalein as a potent antifungal agent against Candida albicans: synergy with fluconazole and sustainable production through probiotic-mediated bioconversion

mycolabadmin

Baicalein, a natural compound from a traditional medicinal plant, is significantly more effective at fighting Candida albicans infections than its parent compound baicalin. When combined with the common antifungal drug fluconazole, baicalein creates a powerful synergistic effect that is especially useful against drug-resistant fungal strains. Scientists discovered that a beneficial probiotic bacterium, Lactobacillus rhamnosus, can efficiently convert the abundant baicalin into baicalein, providing a sustainable and safe way to produce this potent antifungal compound at scale.

Refractory fungal infection: Three case reports highlighting good practice

mycolabadmin

This case series examines three patients with serious fungal infections that did not respond well to standard antifungal treatments. The cases demonstrate how fungi can develop resistance to common antifungal drugs like azoles, making infections harder to treat. The authors emphasize that accurate identification of the fungus, testing its sensitivity to drugs, monitoring drug levels in the blood, and careful use of antifungal medications are essential for successfully treating these difficult infections.

Beyond division and morphogenesis: Considering the emerging roles of septins in plasma membrane homeostasis and cell wall integrity in human fungal pathogens

mycolabadmin

Septins are protein structures inside fungal cells that help them divide and maintain their outer layers. This review explains how these proteins play crucial roles in fungal infections by helping pathogens survive stress conditions and respond to host defenses. By understanding how septins work, scientists might develop new antifungal medications that target these proteins to fight stubborn fungal infections.

Protein kinase A signaling regulates immune evasion by shaving and concealing fungal β-1,3-glucan

mycolabadmin

Candida albicans, a common fungal pathogen, uses a clever strategy to hide from the immune system by masking a molecule on its surface that would normally trigger an immune response. Researchers used both computer modeling and laboratory experiments to show that this hiding strategy involves two main processes: the fungus grows and exposes the molecule, while simultaneously using enzymes to shave it away. They found that a cellular signaling pathway called PKA is essential for activating these shaving enzymes in response to lactate, a signal from the host environment.

Antifungal persistence: Clinical relevance and mechanisms

mycolabadmin

Some fungal infections don’t respond well to antifungal medications even though the fungi aren’t drug-resistant. This happens because a small percentage of fungal cells enter a dormant, low-energy state that protects them from being killed by the drugs. Understanding how these persistent cells survive and finding ways to target them could help prevent recurring fungal infections and improve treatment outcomes.

Antifungal Potential of Streptomyces-Derived Metabolites Against Fluconazole-Resistant Oral Candida albicans: In vitro Evaluation and Mechanistic Insights

mycolabadmin

Researchers studied a type of soil bacteria called Streptomyces that produces natural compounds with strong antifungal properties. These compounds effectively killed drug-resistant Candida fungal infections that commonly affect cancer patients undergoing radiation therapy. The bacterial extract worked by damaging fungal cell membranes and blocking biofilm formation, which are protective structures the fungus uses to survive. While the results are promising for treating stubborn fungal infections, more research is needed to ensure safety for human patients.

Multilocus sequence typing of Candida albicans isolates from wild and farm animals from southern Italy

mycolabadmin

Researchers in Italy studied a fungus called Candida albicans that can infect both humans and animals. They analyzed samples from chickens, wild boars, and lizards to understand how genetically similar these animal strains are to human infections. They found that animal strains are very similar to human strains, suggesting the fungus could be passed between animals and people. This research highlights the importance of monitoring fungal infections in animals to understand public health risks.

Glycan microarray analysis of Candida-related antibodies in human and mice sera guides biomarker discovery and vaccine development

mycolabadmin

Researchers developed a test using synthetic sugar molecules found on Candida yeast to detect antibodies in blood from infected patients and mice. They discovered that the immune system produces different antibodies at different stages of infection, starting with antibodies against certain sugars and later focusing on others. The study identified three specific sugar structures that could be used to create simple blood tests to diagnose Candida infections and potentially develop vaccines to prevent these serious fungal infections.

Correction to: Candida albicans—A systematic review to inform the World Health Organization Fungal Priority Pathogens List

mycolabadmin

This is a correction notice to an important scientific review about Candida albicans, a common fungal infection that affects many people worldwide. The World Health Organization requested this systematic review to help prioritize which fungal diseases are most important to address globally. The correction simply fixes an author’s name that was misspelled in the original published version of the review.

Overexpression of efflux pump and biofilm associated genes in itraconazole resistant Candida albicans isolates causing onychomycosis

mycolabadmin

Researchers studied why some fungal nail infections caused by Candida albicans stop responding to the antifungal drug itraconazole. They found that resistant fungal cells have higher activity of genes that pump the drug out of cells and produce slimy protective coatings called biofilms. These resistant fungi also formed less dense biofilms when the drug was present from the start. Understanding these resistance mechanisms could help develop new treatments by targeting the pump systems or breaking down the protective biofilm layers.

Research Topic: Candida albicans